nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—CYP2D6—Hydroxyurea—head and neck cancer	0.297	0.739	CbGbCtD
Metoclopramide—CYP2D6—Vinblastine—head and neck cancer	0.105	0.261	CbGbCtD
Metoclopramide—Hepatotoxicity—Hydroxyurea—head and neck cancer	0.0135	0.0426	CcSEcCtD
Metoclopramide—Amenorrhoea—Hydroxyurea—head and neck cancer	0.0119	0.0374	CcSEcCtD
Metoclopramide—Menstruation irregular—Docetaxel—head and neck cancer	0.00979	0.0309	CcSEcCtD
Metoclopramide—Rash maculo-papular—Hydroxyurea—head and neck cancer	0.00948	0.0299	CcSEcCtD
Metoclopramide—Supraventricular tachycardia—Docetaxel—head and neck cancer	0.00827	0.0261	CcSEcCtD
Metoclopramide—Hepatotoxicity—Docetaxel—head and neck cancer	0.00702	0.0221	CcSEcCtD
Metoclopramide—Rash maculo-papular—Fluorouracil—head and neck cancer	0.00682	0.0215	CcSEcCtD
Metoclopramide—Depression—Vinblastine—head and neck cancer	0.00638	0.0201	CcSEcCtD
Metoclopramide—Amenorrhoea—Docetaxel—head and neck cancer	0.00617	0.0194	CcSEcCtD
Metoclopramide—Neutropenia—Hydroxyurea—head and neck cancer	0.00612	0.0193	CcSEcCtD
Metoclopramide—Agranulocytosis—Vinblastine—head and neck cancer	0.00597	0.0188	CcSEcCtD
Metoclopramide—Drowsiness—Hydroxyurea—head and neck cancer	0.00584	0.0184	CcSEcCtD
Metoclopramide—Respiratory failure—Docetaxel—head and neck cancer	0.00552	0.0174	CcSEcCtD
Metoclopramide—Hallucination—Hydroxyurea—head and neck cancer	0.00521	0.0164	CcSEcCtD
Metoclopramide—Cardiac arrest—Fluorouracil—head and neck cancer	0.00518	0.0163	CcSEcCtD
Metoclopramide—Fluid retention—Docetaxel—head and neck cancer	0.00515	0.0162	CcSEcCtD
Metoclopramide—Leukopenia—Vinblastine—head and neck cancer	0.00448	0.0141	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Docetaxel—head and neck cancer	0.00434	0.0137	CcSEcCtD
Metoclopramide—Convulsion—Vinblastine—head and neck cancer	0.00433	0.0137	CcSEcCtD
Metoclopramide—Hypertension—Vinblastine—head and neck cancer	0.00432	0.0136	CcSEcCtD
Metoclopramide—Atrial fibrillation—Docetaxel—head and neck cancer	0.00415	0.0131	CcSEcCtD
Metoclopramide—Visual disturbance—Docetaxel—head and neck cancer	0.00415	0.0131	CcSEcCtD
Metoclopramide—Renal impairment—Docetaxel—head and neck cancer	0.00413	0.013	CcSEcCtD
Metoclopramide—Leukopenia—Hydroxyurea—head and neck cancer	0.00408	0.0129	CcSEcCtD
Metoclopramide—Convulsion—Hydroxyurea—head and neck cancer	0.00395	0.0125	CcSEcCtD
Metoclopramide—Agranulocytosis—Fluorouracil—head and neck cancer	0.00392	0.0124	CcSEcCtD
Metoclopramide—Oedema—Hydroxyurea—head and neck cancer	0.00372	0.0117	CcSEcCtD
Metoclopramide—Feeling abnormal—Vinblastine—head and neck cancer	0.00336	0.0106	CcSEcCtD
Metoclopramide—Bronchospasm—Docetaxel—head and neck cancer	0.00334	0.0105	CcSEcCtD
Metoclopramide—Dyspnoea—Hydroxyurea—head and neck cancer	0.00332	0.0105	CcSEcCtD
Metoclopramide—Somnolence—Hydroxyurea—head and neck cancer	0.00331	0.0104	CcSEcCtD
Metoclopramide—Fatigue—Hydroxyurea—head and neck cancer	0.00321	0.0101	CcSEcCtD
Metoclopramide—Neutropenia—Docetaxel—head and neck cancer	0.00318	0.01	CcSEcCtD
Metoclopramide—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00307	0.00967	CcSEcCtD
Metoclopramide—Hypersensitivity—Vinblastine—head and neck cancer	0.00301	0.00948	CcSEcCtD
Metoclopramide—Jaundice—Docetaxel—head and neck cancer	0.00296	0.00932	CcSEcCtD
Metoclopramide—Body temperature increased—Hydroxyurea—head and neck cancer	0.00294	0.00928	CcSEcCtD
Metoclopramide—Leukopenia—Fluorouracil—head and neck cancer	0.00294	0.00926	CcSEcCtD
Metoclopramide—Asthenia—Vinblastine—head and neck cancer	0.00293	0.00923	CcSEcCtD
Metoclopramide—Convulsion—Fluorouracil—head and neck cancer	0.00284	0.00897	CcSEcCtD
Metoclopramide—Agranulocytosis—Docetaxel—head and neck cancer	0.00283	0.00892	CcSEcCtD
Metoclopramide—Diarrhoea—Vinblastine—head and neck cancer	0.00279	0.0088	CcSEcCtD
Metoclopramide—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00274	0.00865	CcSEcCtD
Metoclopramide—Confusional state—Fluorouracil—head and neck cancer	0.0027	0.00852	CcSEcCtD
Metoclopramide—Dizziness—Vinblastine—head and neck cancer	0.0027	0.00851	CcSEcCtD
Metoclopramide—Oedema—Fluorouracil—head and neck cancer	0.00268	0.00845	CcSEcCtD
Metoclopramide—Asthenia—Hydroxyurea—head and neck cancer	0.00267	0.00842	CcSEcCtD
Metoclopramide—Visual impairment—Docetaxel—head and neck cancer	0.00262	0.00827	CcSEcCtD
Metoclopramide—Tachycardia—Fluorouracil—head and neck cancer	0.00261	0.00824	CcSEcCtD
Metoclopramide—Headache—Vinblastine—head and neck cancer	0.00256	0.00806	CcSEcCtD
Metoclopramide—Diarrhoea—Hydroxyurea—head and neck cancer	0.00255	0.00803	CcSEcCtD
Metoclopramide—Flushing—Docetaxel—head and neck cancer	0.00253	0.00796	CcSEcCtD
Metoclopramide—Hypotension—Fluorouracil—head and neck cancer	0.0025	0.00789	CcSEcCtD
Metoclopramide—Dizziness—Hydroxyurea—head and neck cancer	0.00246	0.00776	CcSEcCtD
Metoclopramide—Nausea—Vinblastine—head and neck cancer	0.00242	0.00764	CcSEcCtD
Metoclopramide—Insomnia—Fluorouracil—head and neck cancer	0.00242	0.00764	CcSEcCtD
Metoclopramide—Dyspnoea—Fluorouracil—head and neck cancer	0.00239	0.00753	CcSEcCtD
Metoclopramide—Somnolence—Fluorouracil—head and neck cancer	0.00238	0.00751	CcSEcCtD
Metoclopramide—Rash—Hydroxyurea—head and neck cancer	0.00235	0.0074	CcSEcCtD
Metoclopramide—Dermatitis—Hydroxyurea—head and neck cancer	0.00234	0.00739	CcSEcCtD
Metoclopramide—Headache—Hydroxyurea—head and neck cancer	0.00233	0.00735	CcSEcCtD
Metoclopramide—CYP2D6—Melatonin metabolism and effects—CYP1A1—head and neck cancer	0.00231	0.00824	CbGpPWpGaD
Metoclopramide—CYP11B1—Metapathway biotransformation—GSTM1—head and neck cancer	0.00229	0.00816	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—KISS1—head and neck cancer	0.00229	0.00815	CbGpPWpGaD
Metoclopramide—Muscle spasms—Docetaxel—head and neck cancer	0.00228	0.00718	CcSEcCtD
Metoclopramide—CYP11B1—Corticotropin-releasing hormone—BCL2—head and neck cancer	0.00227	0.0081	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—UROD—head and neck cancer	0.00224	0.008	CbGpPWpGaD
Metoclopramide—Nausea—Hydroxyurea—head and neck cancer	0.00221	0.00697	CcSEcCtD
Metoclopramide—Feeling abnormal—Fluorouracil—head and neck cancer	0.00221	0.00696	CcSEcCtD
Metoclopramide—CYP11B1—Biological oxidations—CYP1A1—head and neck cancer	0.0022	0.00784	CbGpPWpGaD
Metoclopramide—CHRM1—G alpha (q) signalling events—KISS1—head and neck cancer	0.00219	0.00782	CbGpPWpGaD
Metoclopramide—CYP17A1—Biological oxidations—GSTM1—head and neck cancer	0.00217	0.00774	CbGpPWpGaD
Metoclopramide—CYP11B1—Metapathway biotransformation—CYP1A1—head and neck cancer	0.00217	0.00773	CbGpPWpGaD
Metoclopramide—CYP17A1—Metapathway biotransformation—GSTM1—head and neck cancer	0.00214	0.00763	CbGpPWpGaD
Metoclopramide—Urticaria—Fluorouracil—head and neck cancer	0.00213	0.00671	CcSEcCtD
Metoclopramide—Leukopenia—Docetaxel—head and neck cancer	0.00212	0.00669	CcSEcCtD
Metoclopramide—Body temperature increased—Fluorouracil—head and neck cancer	0.00212	0.00668	CcSEcCtD
Metoclopramide—Palpitations—Docetaxel—head and neck cancer	0.00209	0.0066	CcSEcCtD
Metoclopramide—HTR4—Signaling by GPCR—KISS1—head and neck cancer	0.00208	0.0074	CbGpPWpGaD
Metoclopramide—CYP17A1—Biological oxidations—CYP1A1—head and neck cancer	0.00206	0.00733	CbGpPWpGaD
Metoclopramide—Convulsion—Docetaxel—head and neck cancer	0.00205	0.00647	CcSEcCtD
Metoclopramide—Hypertension—Docetaxel—head and neck cancer	0.00205	0.00645	CcSEcCtD
Metoclopramide—CYP17A1—Metapathway biotransformation—CYP1A1—head and neck cancer	0.00203	0.00723	CbGpPWpGaD
Metoclopramide—CYP11B1—Corticotropin-releasing hormone—IL2—head and neck cancer	0.002	0.00713	CbGpPWpGaD
Metoclopramide—Hypersensitivity—Fluorouracil—head and neck cancer	0.00197	0.00622	CcSEcCtD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—head and neck cancer	0.00196	0.00699	CbGpPWpGaD
Metoclopramide—Confusional state—Docetaxel—head and neck cancer	0.00195	0.00615	CcSEcCtD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.00194	0.00691	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—UROD—head and neck cancer	0.00193	0.0069	CbGpPWpGaD
Metoclopramide—Oedema—Docetaxel—head and neck cancer	0.00193	0.0061	CcSEcCtD
Metoclopramide—Tachycardia—Docetaxel—head and neck cancer	0.00189	0.00595	CcSEcCtD
Metoclopramide—HTR4—GPCR downstream signaling—GRP—head and neck cancer	0.00188	0.00671	CbGpPWpGaD
Metoclopramide—Diarrhoea—Fluorouracil—head and neck cancer	0.00183	0.00578	CcSEcCtD
Metoclopramide—CYP17A1—Metabolism—UROD—head and neck cancer	0.00181	0.00645	CbGpPWpGaD
Metoclopramide—Hypotension—Docetaxel—head and neck cancer	0.00181	0.0057	CcSEcCtD
Metoclopramide—CHRM1—G alpha (q) signalling events—GRP—head and neck cancer	0.00181	0.00644	CbGpPWpGaD
Metoclopramide—Dizziness—Fluorouracil—head and neck cancer	0.00177	0.00559	CcSEcCtD
Metoclopramide—Insomnia—Docetaxel—head and neck cancer	0.00175	0.00551	CcSEcCtD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.00174	0.00621	CbGpPWpGaD
Metoclopramide—Dyspnoea—Docetaxel—head and neck cancer	0.00172	0.00544	CcSEcCtD
Metoclopramide—Somnolence—Docetaxel—head and neck cancer	0.00172	0.00542	CcSEcCtD
Metoclopramide—HTR4—Signaling by GPCR—GRP—head and neck cancer	0.00171	0.00609	CbGpPWpGaD
Metoclopramide—Rash—Fluorouracil—head and neck cancer	0.00169	0.00533	CcSEcCtD
Metoclopramide—Dermatitis—Fluorouracil—head and neck cancer	0.00169	0.00532	CcSEcCtD
Metoclopramide—Headache—Fluorouracil—head and neck cancer	0.00168	0.00529	CcSEcCtD
Metoclopramide—Fatigue—Docetaxel—head and neck cancer	0.00167	0.00526	CcSEcCtD
Metoclopramide—DRD2—Hypothetical Network for Drug Addiction—MAPK3—head and neck cancer	0.00162	0.00579	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—head and neck cancer	0.00162	0.00576	CbGpPWpGaD
Metoclopramide—CYP11B1—Corticotropin-releasing hormone—MAPK3—head and neck cancer	0.00161	0.00573	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.0016	0.00569	CbGpPWpGaD
Metoclopramide—Feeling abnormal—Docetaxel—head and neck cancer	0.00159	0.00502	CcSEcCtD
Metoclopramide—Nausea—Fluorouracil—head and neck cancer	0.00159	0.00502	CcSEcCtD
Metoclopramide—DRD2—Hypothetical Network for Drug Addiction—MAPK1—head and neck cancer	0.00154	0.00551	CbGpPWpGaD
Metoclopramide—CYP11B1—Corticotropin-releasing hormone—MAPK1—head and neck cancer	0.00153	0.00545	CbGpPWpGaD
Metoclopramide—Body temperature increased—Docetaxel—head and neck cancer	0.00153	0.00482	CcSEcCtD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.0015	0.00535	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.00148	0.00529	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—KISS1—head and neck cancer	0.00148	0.00527	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	0.00145	0.00518	CbGpPWpGaD
Metoclopramide—Hypersensitivity—Docetaxel—head and neck cancer	0.00142	0.00449	CcSEcCtD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	0.0014	0.00501	CbGpPWpGaD
Metoclopramide—Asthenia—Docetaxel—head and neck cancer	0.00139	0.00437	CcSEcCtD
Metoclopramide—Diarrhoea—Docetaxel—head and neck cancer	0.00132	0.00417	CcSEcCtD
Metoclopramide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.00129	0.00461	CbGpPWpGaD
Metoclopramide—Dizziness—Docetaxel—head and neck cancer	0.00128	0.00403	CcSEcCtD
Metoclopramide—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.00127	0.00455	CbGpPWpGaD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—VEGFA—head and neck cancer	0.00127	0.00451	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—KISS1—head and neck cancer	0.00123	0.00437	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.00122	0.00436	CbGpPWpGaD
Metoclopramide—Rash—Docetaxel—head and neck cancer	0.00122	0.00384	CcSEcCtD
Metoclopramide—Dermatitis—Docetaxel—head and neck cancer	0.00122	0.00384	CcSEcCtD
Metoclopramide—DRD3—GPCR ligand binding—GRP—head and neck cancer	0.00122	0.00434	CbGpPWpGaD
Metoclopramide—Headache—Docetaxel—head and neck cancer	0.00121	0.00382	CcSEcCtD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	0.0012	0.00426	CbGpPWpGaD
Metoclopramide—CYP2D6—Biological oxidations—NAT2—head and neck cancer	0.00119	0.00424	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—TYMS—head and neck cancer	0.00117	0.00419	CbGpPWpGaD
Metoclopramide—CYP2D6—Metapathway biotransformation—NAT2—head and neck cancer	0.00117	0.00418	CbGpPWpGaD
Metoclopramide—Nausea—Docetaxel—head and neck cancer	0.00115	0.00362	CcSEcCtD
Metoclopramide—DRD2—GPCR ligand binding—KISS1—head and neck cancer	0.00113	0.00403	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—KISS1—head and neck cancer	0.00111	0.00394	CbGpPWpGaD
Metoclopramide—CYP11B1—Corticotropin-releasing hormone—AKT1—head and neck cancer	0.00108	0.00387	CbGpPWpGaD
Metoclopramide—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.00105	0.00373	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—GRP—head and neck cancer	0.00101	0.0036	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	0.00099	0.00353	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—STAT6—head and neck cancer	0.00098	0.00349	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	0.00098	0.00349	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—NAT2—head and neck cancer	0.000932	0.00332	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—GRP—head and neck cancer	0.000931	0.00332	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—GRP—head and neck cancer	0.000911	0.00325	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—TYMS—head and neck cancer	0.000898	0.0032	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—TYMS—head and neck cancer	0.000879	0.00314	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—YAP1—head and neck cancer	0.000867	0.00309	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	0.000853	0.00304	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	0.000845	0.00301	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—KISS1—head and neck cancer	0.000835	0.00298	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—DPYD—head and neck cancer	0.000817	0.00291	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—NAT2—head and neck cancer	0.000803	0.00286	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	0.000798	0.00285	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	0.00079	0.00282	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—YAP1—head and neck cancer	0.000776	0.00277	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—KISS1—head and neck cancer	0.000758	0.0027	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—NAT2—head and neck cancer	0.000751	0.00268	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—DPYD—head and neck cancer	0.000704	0.00251	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—GRP—head and neck cancer	0.000687	0.00245	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—YAP1—head and neck cancer	0.000668	0.00238	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—DPYD—head and neck cancer	0.000659	0.00235	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—KISS1—head and neck cancer	0.000639	0.00228	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—YAP1—head and neck cancer	0.000625	0.00223	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—KISS1—head and neck cancer	0.000625	0.00223	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—GRP—head and neck cancer	0.000624	0.00223	CbGpPWpGaD
Metoclopramide—CYP2D6—Biological oxidations—GSTM1—head and neck cancer	0.000587	0.00209	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	0.000583	0.00208	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—KISS1—head and neck cancer	0.00058	0.00207	CbGpPWpGaD
Metoclopramide—CYP2D6—Metapathway biotransformation—GSTM1—head and neck cancer	0.000579	0.00206	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—PTEN—head and neck cancer	0.000571	0.00203	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—KISS1—head and neck cancer	0.000568	0.00202	CbGpPWpGaD
Metoclopramide—CYP2D6—Biological oxidations—CYP1A1—head and neck cancer	0.000556	0.00198	CbGpPWpGaD
Metoclopramide—CYP2D6—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000549	0.00196	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—GRP—head and neck cancer	0.000526	0.00187	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—GRP—head and neck cancer	0.000515	0.00183	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	0.000508	0.00181	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	0.000502	0.00179	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—IL2—head and neck cancer	0.000501	0.00179	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—UROD—head and neck cancer	0.000489	0.00174	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—GRP—head and neck cancer	0.000478	0.0017	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	0.00047	0.00167	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—GRP—head and neck cancer	0.000467	0.00167	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—TYMS—head and neck cancer	0.000466	0.00166	CbGpPWpGaD
Metoclopramide—CHRM1—Regulation of Actin Cytoskeleton—MAPK3—head and neck cancer	0.000464	0.00165	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—GSTM1—head and neck cancer	0.00046	0.00164	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—IL2—head and neck cancer	0.000455	0.00162	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—KISS1—head and neck cancer	0.000448	0.0016	CbGpPWpGaD
Metoclopramide—CHRM1—Regulation of Actin Cytoskeleton—MAPK1—head and neck cancer	0.000441	0.00157	CbGpPWpGaD
Metoclopramide—CHRM1—Regulation of Actin Cytoskeleton—EGFR—head and neck cancer	0.000441	0.00157	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—GPX1—head and neck cancer	0.000441	0.00157	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	0.000438	0.00156	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—PTEN—head and neck cancer	0.000437	0.00156	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—CYP1A1—head and neck cancer	0.000436	0.00156	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—PTEN—head and neck cancer	0.000427	0.00152	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	0.00041	0.00146	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—TYMS—head and neck cancer	0.000401	0.00143	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—GSTM1—head and neck cancer	0.000397	0.00141	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—NOTCH1—head and neck cancer	0.000391	0.00139	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—TP53—head and neck cancer	0.000389	0.00139	CbGpPWpGaD
Metoclopramide—CHRM1—Regulation of Actin Cytoskeleton—PIK3CA—head and neck cancer	0.000383	0.00137	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—GPX1—head and neck cancer	0.00038	0.00135	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—CYP1A1—head and neck cancer	0.000376	0.00134	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—TYMS—head and neck cancer	0.000375	0.00134	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—GSTM1—head and neck cancer	0.000371	0.00132	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—GRP—head and neck cancer	0.000369	0.00131	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—MAPK3—head and neck cancer	0.000366	0.00131	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	0.000359	0.00128	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—STAT6—head and neck cancer	0.000358	0.00128	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—GPX1—head and neck cancer	0.000355	0.00127	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—CYP1A1—head and neck cancer	0.000352	0.00125	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—MAPK1—head and neck cancer	0.000348	0.00124	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—EGFR—head and neck cancer	0.000348	0.00124	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	0.000346	0.00123	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—KISS1—head and neck cancer	0.000343	0.00122	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—KISS1—head and neck cancer	0.000335	0.0012	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—PIK3CA—head and neck cancer	0.000333	0.00119	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	0.000329	0.00117	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	0.000329	0.00117	CbGpPWpGaD
Metoclopramide—CHRM1—G alpha (q) signalling events—PIK3CA—head and neck cancer	0.000319	0.00114	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—YAP1—head and neck cancer	0.000317	0.00113	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	0.000309	0.0011	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—PIK3CA—head and neck cancer	0.000302	0.00108	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—TP53—head and neck cancer	0.000298	0.00106	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—TP53—head and neck cancer	0.000292	0.00104	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	0.000289	0.00103	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	0.000286	0.00102	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—GRP—head and neck cancer	0.000282	0.00101	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—HRAS—head and neck cancer	0.00028	0.000997	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—GRP—head and neck cancer	0.000276	0.000984	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—STAT6—head and neck cancer	0.000274	0.000976	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—AKT1—head and neck cancer	0.000272	0.00097	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IL2—head and neck cancer	0.000269	0.000959	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—STAT6—head and neck cancer	0.000268	0.000956	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	0.000264	0.000942	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CCND1—head and neck cancer	0.000262	0.000935	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PTGS2—head and neck cancer	0.00026	0.000925	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PTEN—head and neck cancer	0.000253	0.000902	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—AKT1—head and neck cancer	0.000247	0.00088	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—YAP1—head and neck cancer	0.000242	0.000864	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—YAP1—head and neck cancer	0.000237	0.000846	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—VEGFA—head and neck cancer	0.000229	0.000815	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—STAT3—head and neck cancer	0.000226	0.000807	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PTEN—head and neck cancer	0.000226	0.000807	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PTGS2—head and neck cancer	0.000224	0.000797	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MAPK3—head and neck cancer	0.000216	0.000771	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PTGS2—head and neck cancer	0.000209	0.000746	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MAPK1—head and neck cancer	0.000206	0.000734	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—EGFR—head and neck cancer	0.000206	0.000734	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NAT2—head and neck cancer	0.000203	0.000724	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PTEN—head and neck cancer	0.000195	0.000695	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—IL2—head and neck cancer	0.000183	0.000653	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PTEN—head and neck cancer	0.000182	0.000651	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PIK3CA—head and neck cancer	0.000179	0.000637	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—DPYD—head and neck cancer	0.000178	0.000635	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TP53—head and neck cancer	0.000173	0.000616	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—YAP1—head and neck cancer	0.000169	0.000603	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL2—head and neck cancer	0.000166	0.000593	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—HRAS—head and neck cancer	0.000165	0.000589	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PIK3CA—head and neck cancer	0.00016	0.000569	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—AKT1—head and neck cancer	0.000146	0.00052	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NOTCH1—head and neck cancer	0.000143	0.000509	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—IL2—head and neck cancer	0.00014	0.0005	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PIK3CA—head and neck cancer	0.000138	0.000491	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—IL2—head and neck cancer	0.000137	0.000489	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—MAPK3—head and neck cancer	0.000134	0.000477	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—AKT1—head and neck cancer	0.00013	0.000465	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PIK3CA—head and neck cancer	0.000129	0.000459	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL2—head and neck cancer	0.000127	0.000454	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—MAPK1—head and neck cancer	0.000127	0.000454	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—EGFR—head and neck cancer	0.000127	0.000453	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL2—head and neck cancer	0.000125	0.000444	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—PIK3CA—head and neck cancer	0.000122	0.000433	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—AKT1—head and neck cancer	0.000112	0.000401	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—PIK3CA—head and neck cancer	0.00011	0.000394	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NOTCH1—head and neck cancer	0.000109	0.000389	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NOTCH1—head and neck cancer	0.000107	0.000381	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—AKT1—head and neck cancer	0.000105	0.000375	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—MAPK3—head and neck cancer	0.000102	0.000365	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—HRAS—head and neck cancer	0.000102	0.000364	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—TYMS—head and neck cancer	0.000102	0.000362	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSTM1—head and neck cancer	0.0001	0.000358	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—MAPK3—head and neck cancer	0.0001	0.000357	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—AKT1—head and neck cancer	9.93e-05	0.000354	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL2—head and neck cancer	9.82e-05	0.00035	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—MAPK1—head and neck cancer	9.73e-05	0.000347	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—EGFR—head and neck cancer	9.73e-05	0.000347	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GPX1—head and neck cancer	9.61e-05	0.000343	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCND1—head and neck cancer	9.58e-05	0.000341	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—MAPK1—head and neck cancer	9.53e-05	0.00034	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—EGFR—head and neck cancer	9.52e-05	0.00034	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP1A1—head and neck cancer	9.51e-05	0.000339	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—PIK3CA—head and neck cancer	9.3e-05	0.000332	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PTEN—head and neck cancer	9.24e-05	0.00033	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—PIK3CA—head and neck cancer	9.1e-05	0.000325	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—AKT1—head and neck cancer	9.02e-05	0.000322	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—PIK3CA—head and neck cancer	8.45e-05	0.000301	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—VEGFA—head and neck cancer	8.35e-05	0.000298	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—STAT3—head and neck cancer	8.27e-05	0.000295	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—PIK3CA—head and neck cancer	8.27e-05	0.000295	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MAPK3—head and neck cancer	7.9e-05	0.000282	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—HRAS—head and neck cancer	7.81e-05	0.000279	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—HRAS—head and neck cancer	7.65e-05	0.000273	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—AKT1—head and neck cancer	7.6e-05	0.000271	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL2—head and neck cancer	7.52e-05	0.000268	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MAPK1—head and neck cancer	7.51e-05	0.000268	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—EGFR—head and neck cancer	7.51e-05	0.000268	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—AKT1—head and neck cancer	7.44e-05	0.000265	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL2—head and neck cancer	7.36e-05	0.000262	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCND1—head and neck cancer	7.33e-05	0.000261	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCND1—head and neck cancer	7.17e-05	0.000256	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PTEN—head and neck cancer	7.07e-05	0.000252	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PTEN—head and neck cancer	6.92e-05	0.000247	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—AKT1—head and neck cancer	6.9e-05	0.000246	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—AKT1—head and neck cancer	6.75e-05	0.000241	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PIK3CA—head and neck cancer	6.52e-05	0.000232	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—VEGFA—head and neck cancer	6.39e-05	0.000228	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—STAT3—head and neck cancer	6.33e-05	0.000226	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TP53—head and neck cancer	6.31e-05	0.000225	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—VEGFA—head and neck cancer	6.25e-05	0.000223	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—STAT3—head and neck cancer	6.19e-05	0.000221	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MAPK3—head and neck cancer	6.04e-05	0.000215	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HRAS—head and neck cancer	6.03e-05	0.000215	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MAPK3—head and neck cancer	5.91e-05	0.000211	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MAPK1—head and neck cancer	5.75e-05	0.000205	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EGFR—head and neck cancer	5.75e-05	0.000205	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTGS2—head and neck cancer	5.66e-05	0.000202	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MAPK1—head and neck cancer	5.63e-05	0.000201	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EGFR—head and neck cancer	5.63e-05	0.000201	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—AKT1—head and neck cancer	5.33e-05	0.00019	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PIK3CA—head and neck cancer	4.99e-05	0.000178	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTEN—head and neck cancer	4.93e-05	0.000176	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PIK3CA—head and neck cancer	4.88e-05	0.000174	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TP53—head and neck cancer	4.83e-05	0.000172	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TP53—head and neck cancer	4.72e-05	0.000168	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HRAS—head and neck cancer	4.62e-05	0.000165	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HRAS—head and neck cancer	4.52e-05	0.000161	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—AKT1—head and neck cancer	4.08e-05	0.000145	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—AKT1—head and neck cancer	3.99e-05	0.000142	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PIK3CA—head and neck cancer	3.48e-05	0.000124	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—AKT1—head and neck cancer	2.84e-05	0.000101	CbGpPWpGaD
